UN MODELO MICROFLUÍDICO DE TEJIDO CIRRÓTICO HUMANO REVELA LA CAPACIDAD ANTIFIBRÓTICA DE LIRAGLUTIDA MEDIANTE LA DESACTIVACIÓN DE LAS CÉLULAS HEPÁTICAS ESTRELLADAS Y EL REMODELADO DE LA MATRIZ EXTRACELULAR
María Andrés-Rozas, Jordi Gracia-Sancho, Anabel Fernández-Iglesias(Centro de Investigación Biomédica en Red), Yiliam Fundora, Sergi Guixé-Muntet, Rosa Villa, G. Chullo(Hospital Clínic de Barcelona), Guofeng Liu, Peio Aristu-Zabalza(Departament de Salut)
Cited by 0
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical
|Nutrients|2020|26
A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
|Nutrients|2019|22
Focusing on Ischemic Reperfusion Injury in the New Era of Dynamic Machine Perfusion in Liver Transplantation
|International Journal of Molecular Sciences|2024|20